Shares of ResMed Inc. RMD slipped 3.97% to $204.54 Tuesday, on what proved to be an all-around poor trading session for the ...

Shares of ResMed Inc. RMD rallied 3.82% to $213.00 Monday, on what proved to be an all-around rough trading session for the ...

In a welcome move, ResMed saw its Relative Strength Rating rise from 65 to 78 on Tuesday. Please watch the video at Investors ...

ResMed RMD shares rallied 3.8% in the last trading session to close at $213. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This ...

SAN DIEGO – Resmed has announced that its home sleep apnea test, NightOwl, is now available across the U.S.

BofA lowered the firm’s price target on ResMed (RMD) to $280 from $290 and keeps a Buy rating on the shares. The firm updated its model for ...

Professional networking site LinkedIn has put together its annual list of Australia's best workplaces for career growth ...

NightOwl is now widely available across the United States. Individuals interested in NightOwl should speak with their healthcare provider for more information. To learn more, visit: https://www.resmed ...

StockNews.com downgraded shares of ResMed (NYSE:RMD – Free Report) from a buy rating to a hold rating in a research report report published on Wednesday morning. A number of other equities research ...

Home CPAP device maker Resmed is launching a small, disposable wearable to help diagnose cases of obstructive sleep apnea.  | ...

People have complained about Apple Vision Pro's weight, so ResMed built the Kontor Head Strap that helps by adding ...

SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its ...